Small animal cardiovascular magnetic resonance can provide cogent data to support clinical observations. [20] [21] [22] [23] [24] [25] [26] [27] To validate in vivo T 1 mapping as a means to measure diffuse fibrosis, we performed serial cardiac MRI in mice with pressure-overload hypertrophy induced by transverse aortic constriction (TAC). Using this model, we were able to control factors that complicate or are prohibitive in studies of patients and volunteers, including the ability to image serially, before and after the onset of disease, and the provision of whole hearts for histological, molecular, and biochemical evaluation, minimizing sample error. Our aim was to test whether in vivo T 1 mapping in addition to LGE-MRI could detect diffuse and focal cardiac fibrosis after TAC and whether both techniques were sensitive to the pharmacological reduction of fibrosis by angiotensin receptor blockade using losartan. 28, 29 In vivo measurements were validated against the quantitative whole heart collagen volume fraction, myocyte cross-sectional area (CSA), and quantitative reverse transcription polymerase chain reaction (PCR) for fibrotic and hypertrophic markers.
Methods
A detailed description of surgery, drug treatment, imaging, histology, quantitative reverse transcription PCR, and statistical analysis is provided in the Data Supplement.
Surgery and Drug Treatment
Animal procedures complied with European Union Directive 2010/63/European Union and the UK Animals Scientific Procedure Act 1986 and were approved by Imperial College Animal Ethics Review Committees and the Home Office (London, United Kingdom). One week before surgery and throughout the study, half of the 12-week-old male C57/BL6 mice were given losartan (Cozaar, Merck, Frankfurt, Germany) in the drinking water (1 g/L). Mice were subjected to TAC (n=21) or sham operation (n=8). Overall survival was 76% (sham, n=4; TAC, n=8; sham+losartan, n=4; TAC+losartan, n=6). Echocardiography (Vevo-770, Visualsonics, Toronto, Canada) performed 2 days after surgery confirmed successful aortic constriction by the presence of a visible band around the aortic arch between the right and left common carotid arteries ( Figure 1A and 1B) and a drop in the left-to-right common carotid artery blood flow velocity ratio (sham, 0.77±0.12; TAC, 0.09±0.07; P<0.001; sham+losartan, 0.88±0.12; TAC+losartan, 0.05±0.03; P<0.001; Figure 1C and 1D).
Magnetic Resonance Imaging
Mice were imaged using a 9.4T MRI system (Agilent, Palo Alto, CA) and a 38-mm quadrature-driven birdcage radio frequency coil (Rapid Biomedical, Rimpar, Germany). Cardiac-and respiratory-gated cine-MRI was performed in the true short-axis orientation and covered the whole left ventricle (LV) as described. 30 LGE-MRI was performed 20 and 35 minutes after intraperitoneal injection of 0.5 mmol/kg gadolinium-diethylenetriamine penta acetic acid-bismethylamide (Gd-DTPA-BMA) (Omniscan. GE Healthcare, Hatfield, United Kingdom), using a multi-slice inversion recovery sequence. 24 T 1 mapping was performed before and 25 minutes after contrast injection using a fully relaxed 3-slice look-locker inversion recovery sequence that acquired short-axis gradient echo images at end diastole at every cardiac trigger, giving inversion times of ≈100 ms, after a double-gated nonselective adiabatic inversion pulse 24, 31 (1-mm slice thickness, echo time/repetition time, 1.6/3.2 ms; 10° excitation pulse; 40 inversion times; field of view, 25.6×25.6 mm; matrix size, 128×128; voxel size, 200×200×1000 μm). To allow full relaxation, ≥6 s elapsed between acquisitions. Diastolic function was assessed using high temporal resolution cine-MRI 32 and Doppler echocardiography of mitral valve inflow.
Data were analyzed in a blinded fashion using ImageJ (National Institutes of Health, Bethesda, MD) and MRmap. 33 Standard measures of LV and right ventricular (RV) morphology and function were made from cine stacks. LGE-MRI images were thresholded to the full width at half maximum of enhanced regions to identify areas of signal enhancement. For T 1 analysis, a region of interest was drawn on each image in the ventricular septum, LV free wall, and blood pool of the basal, mid and apical slices pre-and post-Gd infusion. Endocardial and epicardial borders were avoided to reduce blood pool contamination, and areas of focal fibrosis identified in LGE-MRI were excluded. Unless stated otherwise, data were presented as the average of all analyzed regions. Signal intensity at each inversion time was measured, points acquired during respiration removed, data fitted to the exponential curve, and T 1 calculated. Pixelwise T 1 maps were produced using the open source software MRmap 33 after in-house conversion of data to Digital Imaging and Communications in Medicine compliant format. ECV was calculated from pre-and postcontrast T 1 values of myocardium and blood, correcting for the hematocrit measured at sacrifice. 23
Statistical Analysis
Statistical analysis was performed with GraphPad Prism versions 5.02 and 6. Data are presented as mean±SD. Equality of variance was tested using Brown-Forsythe and Bartlett tests. The majority of data showed equal variance and was analyzed using 2-way ANOVA with Bonferroni post hoc test adjustment of P values for comparisons between the following groups: untreated versus treated sham, untreated versus treated TAC, untreated sham versus treated sham, and untreated TAC versus treated TAC. Data with unequal variance were assessed using Kruskal-Wallis tests. Bivariate correlations of normally distributed data were evaluated using Pearson test.
Results

Cardiac Function
Cardiac morphology and function were measured 7 and 28 days after surgery using cine-MRI ( Figure 2 ; Table) . As expected, [34] [35] [36] LV end-diastolic volumes, end-systolic volumes, and masses were increased after TAC and ejection fractions were reduced. Losartan significantly attenuated the TAC-mediated increase in end-systolic volumes and reduction in ejection fraction ( Figure 2 ; Table) . LV stroke volumes and cardiac outputs were lower in the untreated TAC group at 7 days although not at 28 days. Notably, LV diastolic function was impaired in untreated TAC mice at 28 days, with elevated LV peak filling rates/velocities and reduced E′/A′ ratios, whereas no significant increase occurred in losartan-treated mice (Table) . RV function was also affected by TAC, with end-diastolic volumes and stroke volume reduced in untreated animals at 7 and 28 days (Table) , changes likewise attenuated by losartan. Hence, serial in vivo measurements confirmed that TAC impaired cardiac systolic and diastolic function, and that this effect was attenuated by angiotensin receptor blockade.
Late-Gadolinium Enhancement
In sham-operated mice, no focal regions of LGE were detected 7 or 28 days after surgery. TAC induced focal regions of LGE in 3 of 8 hearts at 7 days, increasing to 6 of 8 hearts at 28 days (P<0.05; Figure 3 ). In losartan-treated mice, TAC induced focal LGE in 3 of 6 animals by 7 days, with no further increase at 28 days, indicating that losartan treatment did not significantly attenuate focal fibrosis. Polar map analysis ( Figure 3) showed that LGE was typically located at the point where the RV inserts into the inferior LV wall (RV insertion point), as found in hypertrophic cardiomyopathy 3, 37 and patients with hypertension. 38 The location of focal fibrosis in picrosirius red-stained tissue sections matched this specific pattern of enhancement in the corresponding LGE images (Figure 3 ). To our knowledge, this is the first demonstration of verified focal fibrosis after TAC by LGE in mice.
T 1 Mapping
T 1 measurements were made in the blood pool and myocardium of pre-and postcontrast inversion recovery look-locker acquisitions ( Figure 4A -4C). A pilot study into the gadolinium kinetics was used to determine when Gd distribution was at equilibrium between the blood pool and myocardium (Figure 4D ). T 1 measurements were made before and repeatedly after contrast administration in 6 control mice. Myocardial and blood T 1 values fell during the first 10 minutes, remained stable for the next 10 minutes, and then slowly increased as contrast was cleared. Importantly, despite these changes in blood and myocardial T 1 , the calculated ECV remained stable from 10 minutes after administration for ≥1 hour (Figure 4 ). The MRI acquisition protocol performed on mice 7 and 28 days after TAC surgery is presented in Figure 4E . T 1 measurements at 7 days acquired before contrast administration showed a small increase in T 1 ECV was similar between groups at 7 days ( Figure 5 and Figure II in the Data Supplement), was increased at 28 days in all regions of untreated TAC hearts (38% overall), and was attenuated by losartan (sham, 16±1%; TAC, 22±2%; P<0.01; sham+losartan, 16±1%; TAC+losartan, 18±4%; P=0.38; TAC versus TAC+losatran, P<0.05; Figure 5 ). ECV at the RV insertion points (excluded from the regional and whole heart analyses of diffuse fibrosis, in view of the focal fibrosis by LGE-MRI) also was significantly greater in untreated TAC mice but not after losartan treatment (sham, 16±2%; TAC, 26±4%; P<0.001; sham+losartan, 16±1%; TAC+losartan, 20±4%; P=0.33). Elevated ECV correlated with reduced ejection fractions ( Figure III in the Data Supplement) and E′/A′ ratios and with increased peak LV filling velocities ( Figure  IV in the Data Supplement), indicating the predicted impact of ECV on systolic and diastolic dysfunction. Hematocrit, essential to the calculation of ECV, showed no significant difference between groups at 28 days (Table) . Hence, TAC acutely elevated precontrast T 1 , possibly owing to edema, 22, 39 and chronically increased the T1-derived ECV, as anticipated for the presence of diffuse fibrosis. These latter changes were specifically reduced by angiotensin receptor blockade.
Tissue Analysis
At sacrifice, heart weights and heart weight:body weight ratios were significantly greater in both TAC groups compared with controls (Table) . Heart sections stained with picrosirius red showed the induction of extensive fibrosis throughout the myocardium by TAC (collagen volume fraction: sham, 0.4±0.03%; TAC, 6.7±1.5%; P<0.001; sham+losartan, 0.5±0.02%; TAC+losartan, 4.8±2.5%; P<0.05), which was significantly reduced by losartan (P<0.05 versus untreated TAC; Figure 6 ). Whereas collagen volume fraction calculated from tissue sections showed weak, although significant correlation with before contrast T 1 (R 2 =0.24; P<0.05), and inverse correlation with after contrast T 1 (R 2 =0.33; P<0.01), there was stronger correlation between collagen volume fraction and the T1-derived ECV (R 2 =0.57; P<0.001; Figure 6 ).
A second histological parameter, myocyte CSA, was increased by TAC even with losartan (sham, 347±36 μm 2 ; TAC, 444±48 μm 2 ; P<0.05; sham+losartan, 337±7 μm 2 ; TAC+losartan, 430±62 μm 2 ; P<0.05; Figure 7 ). There was a weak correlation between myocyte CSA and precontrast T 1 (R 2 =0.32; P<0.01) and postcontrast T 1 (R 2 =0.22; P<0.05). However, the direct linear correlation between myocyte CSA and T1-derived ECV was again stronger (R 2 =0.49; P<0.01; Figure 7 ). Likewise, there was a significant linear correlation between T1-derived ECV and molecular markers of hypertrophy (β-myosin heavy chain, R 2 =0.36, P<0.01; atrial natriuretic peptide, R 2 =0.43, P<0.01).
Discussion
Accurate and sensitive detection of both replacement and interstitial fibrosis is an important clinical challenge.
LGE-MRI has become the method of choice for detection of replacement fibrosis, 4 whereas recent advances in after contrast T 1 and ECV mapping suggest they offer a robust technique for assessment of diffuse fibrosis in patients with myocardial infarction, 14, 40, 41 aortic stenosis, 5, 15 adult congenital heart disease, 5, 9, 14, 16, 42 and heart failure. 11 Reduced T 1 or increased ECV was also found to correlate with histological measurements of fibrosis, 5, 11, 13, 19 lower ejection fraction, 9, 13, 15, 42 and diastolic dysfunction. 11 Here, we found that at 28 but not 7 days after induction of pressure overload in the mouse, there was a significant increase in ECV in the ventricular septum and LV free wall of basal, mid, and apical LV slices. These changes were independent of focal fibrosis, as any regions of LGE were excluded from the analysis. 8 Increased ECV correlated with whole heart collagen volume fraction, reduced ejection fraction, and impaired diastolic function. However, correlations within treatment groups would likely be smaller than those reported. ECV was associated with extent of hypertrophy measured by myocyte CSA and quantitative reverse transcription PCR for β-MHC and ANP. It is important to note that cardiac dysfunction and hypertrophy were relatively low in these mice, 36 meaning that ECV changes are sensitive to mild forms of disease and could offer a sensitive early biomarker for a range of cardiomyopathies.
To test whether ECV was sensitive to pharmacological intervention, we treated TAC mice with the angiotensin II receptor type-1 blocker losartan, which is known to reduce fibrosis in humans 28 and mice. 29 We found that losartan not only attenuated histological measurements of fibrosis but also prevented the increase in ECV, suggesting that MRI measurements of diffuse fibrosis have great potential as a noninvasive end point for assessing novel pharmacological therapies aimed at reducing fibrosis or for monitoring disease progression. Interestingly, losartan did not reduce myocyte CSA, suggesting that ECV changes are directly associated with fibrosis as opposed to hypertrophy. Few studies have accurately detected diffuse fibrosis in vivo in small animal models of cardiac hypertrophy and heart failure. Using standard LGE acquisitions, diffuse fibrosis was identified in a rat model of doxorubicin cardiotoxicity 43 and an mdx mouse model of muscular dystrophy. 25 However, LGE acquisitions have limited sensitivity and are not truly quantifiable when applied to diffuse fibrosis. 1, 5, 9, 11, 12, 17 Single-slice pre and post contrast T 1 mapping was recently applied to rats after angiotensin infusion 23 and to mice after Nω-nitro-l-arginine-methyl-ester administration or TAC. 44, 45 However, in these studies, there was no exclusion of focal fibrosis, assessment of diastolic function, or investigation of sensitivity to therapy. Further, in the case of chronic TAC, only 4 animals were studied, with no controls.
Accurate quantification of ECV requires that contrast agent is distributed equally between plasma and extracellular space. Although the usefulness of bolus followed by constant contrast infusion has been demonstrated, 5 we and others 42, 46 found that a single intraperitoneal bolus rapidly and reproducibly resulted in a dynamic equilibrium between myocardial and blood pool T 1 , hence ECV calculations were accurate from 10 to ≥60 minutes after contrast. By removing the need for constant infusion and using a simple intraperitoneal bolus rather than intravenous infusion, animal sedation time was reduced and successful contrast injection within the magnet was increased. It is possible that at the Gd concentrations used in this study, transcytolemmal water exchange may result in an underestimation of ECV. 45 However, using this basic and clinically applied system, we were still able to identify pharmacologically preventable elevations in ECV.
Recent studies have suggested that before contrast T 1 measurements can directly quantify the extent and severity of acute ischemic injury and may offer a more objective measure of area at risk than the T 2 -weighted imaging currently used. 39 Here, we found that myocardial T 1 was elevated in all regions of the myocardium 7 days after TAC, hypothesized to reflect tissue edema or more severe cellular injury with consequent release of intracellular ions into the extracellular space 22, 39 caused by pressure-induced cell death and inflammation. Increased T 1 correlated with reduced systolic function, highlighting the potential value of this measurement. Differences in T 1 lost significance by 28 days, as initial cell death and inflammation subsided. It is interesting to note that before contrast T 1 at 7 days was elevated in the absence of increased ECV possibly because of increased intracellular water content, rather than an extracellular increase, which would likely elevate ECV. Further in vivo and histological validation is required, but these data indicate that before contrast T 1 mapping could be a useful tool in quantitative assessment of tissue damage.
Although the emphasis of this report is T 1 mapping for diffuse cardiac fibrosis in mice, its use in concert with LGE for focal fibrosis is complementary. LGE has been performed frequently in small animal models of myocardial infarction 20, 24, 26 but rarely in other cardiomyopathies 25, 43 and never in mice after TAC. We found focal areas of fibrosis at the inferior RV insertion point in approximately half of the TAC mice, in agreement with findings from patients with hypertrophic cardiomyopathy 3, 37 and hypertension 38 and is probably owing to increased mechanical wall stress at this site, exacerbating damage and leading to myocyte fiber disarray, inflammation, and fibrosis. 38 The ability to detect patterns of focal fibrosis with similar features to those reported for human cardiomyopathies 47 will be highly beneficial in characterization of small animal models of hypertrophic cardiomyopathy, DCM, myocarditis, and amyloidosis and may give greater mechanistic insight into why the focal patterns of damage occur and how they can be prevented.
The majority of studies performed on TAC mice assess cardiac function by 1-dimensional (1D) and 2D echocardiography, with few studies using cardiac MRI. [34] [35] [36] Here, both were used to make comprehensive in vivo measurements 7 and 28 days after TAC in untreated and losartan-treated mice. TAC induced LV chamber dilation, hypertrophy, and reduced ejection fractions at 7 and 28 days. Under the conditions tested, losartan treatment did not significantly affect end-diastolic volumes or LV mass despite improvements in end-systolic volumes, ejection fraction and peak ejection rate, fibrosis, and ECV. This concurs with studies in other mouse models of hypertrophy, in which fibrosis was more sensitive to losartan than LV mass 29 and highlights the importance of improved means for its assessment noninvasively. In addition, our observation that elevated LV peak filling rates/velocities and reduced E′/A′ ratios in TAC mice did not significantly differ from shams when losartan was administered, coupled with the ECV and collagen volume fraction measurements, supports the interpretation that losartan-mediated retardation of fibrosis may improve myocardial compliance and restore diastolic relaxation and demonstrate how advanced in vivo imaging can give insight into the processes of disease.
For more than 20 years, the microsurgical model of pressureoverload hypertrophy in mice has moved this model organism to the forefront of studies, uniting pathobiological approaches with unique opportunities for genetic dissection of disease pathways and potential countermeasures. The continuous and progressive nature of pathological remodeling makes the hypertrophied heart an excellent target for pharmacological countermeasures before the onset of heart failure. However, methods for noninvasive, serial measurements of diffuse fibrosis have lagged behind the innovations in physiology and genetics. An accurate in vivo method that can monitor the effects of novel drug treatments on cardiac fibrosis would be invaluable, for both agents targeting hypertrophy and agents targeting fibrosis. This use may extend to heart disease of other kinds given the pivotal role of fibrosis in the pathogenesis of hypertrophic cardiomyopathy caused by mutations in sarcomeric protein genes. 29 Our study demonstrates that advanced small-mammal cardiac MRI offers a sensitive, noninvasive tool to detect diffuse fibrosis in vivo, follow its progression over time, and assess experimental therapies targeted at reducing fibrosis in the heart.
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